Gilead Sciences

Diversified biopharma

GILD · Nasdaq · United States

Share price · GILD

$168.98+25.54 (+17.81%) 3M

close as of 2026-11-18 · 24h delayed · vol 5.0M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GILD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+3.1%
  2. 5 Aug 2026-2.6%
  3. 4 Aug 2026+3.1%
  4. 21 Jul 2026-2.2%
  5. 10 Jul 2026-3.7%
  6. 7 Jul 2026+5.2%
  7. 16 Jun 2026+2.4%
  8. 11 Jun 2026+3.6%
  9. 9 Jun 2026-2.0%
  10. 11 Feb 2026+5.8%

Share of unusual movement by asset

For each asset, the share of GILD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Sacituzumab Govitecan
events and moves
95%
Seladelpar (Livdelzi)
events and moves
6shown from 8 days
Lenacapavir (Yeztugo) (Yeztugo)
events and moves
4shown from 8 days
Anitocabtagene autoleucel
events and moves
3shown from 8 days
Bictegravir (Biktarvy)
events and moves
2shown from 8 days
ABI-5366
events and moves
2shown from 8 days
filgotinib (Jyseleca)
events and moves
1shown from 8 days
Bictegravir/lenacapavir (Bixlenvo) (Bixlenvo)
events and moves
1shown from 8 days
Islatravir/lenacapavir
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—10%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—62%

Assets

(27 total)
27Total Assets
13Approved
7Phase 3 / Filed
7Phase 1–2 / Early
13Diseases
Quick filter:
Showing 27 of 27 assets
Target & Modality
Ambrisentan(Letairis)
Approved
Endothelin A receptorSmall molecule
Pulmonary Arterial Hypertension
Bictegravir(Biktarvy)
Approved
HIV integraseSmall molecule
HIV
Approved
HIV integrase · HIV capsidSmall molecule
HIV
Elvitegravir(Stribild)
Approved
HIV integraseSmall molecule
HIV
Approved
HIV reverse transcriptaseSmall molecule
HIV
Approved
HIV reverse transcriptaseSmall molecule
HIV
Approved
HIV capsidSmall molecule
HIV
Approved
HIV capsidSmall molecule
HIV
Approved
TROP2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerBladder / Urothelial CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma
Seladelpar(Livdelzi)
Approved
PPAR-deltaSmall molecule
Cholestatic Liver Disease
Primary Biliary Cholangitis
Approved
HBV polymerase (reverse transcriptase)Small molecule
Chronic Hepatitis B
Approved
HIV reverse transcriptaseSmall molecule
HIV
Approved
HIV reverse transcriptase (RT)Small molecule
HIVChronic Hepatitis B
Phase 3
BCMACell therapy
Multiple Myeloma
filgotinib(Jyseleca)
Phase 3
JAK · JAK1Small molecule
Rheumatoid Arthritis

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(40 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Gamgertamig (CM336)Phase 1/2Multiple Myeloma
Est. primary completion 2026-12 · NCT05299424 · CT.gov ↗
What to watch
Anitocabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2026-12 · NCT05396885 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3Metastatic Breast Cancer
Est. primary completion 2026-12 · NCT04639986 · CT.gov ↗
What to watch
2027 (13)
February 2027 (1)
Sacituzumab GovitecanPhase 3Triple Negative Breast Cancer, PD-L1 Positive
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch
March 2027 (2)
Sacituzumab GovitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-03 · NCT05186974 · CT.gov ↗
What to watch
Lenacapavir (Sunlenca)Phase 2HIV-1-infection
Est. primary completion 2027-03 · NCT06749054 · CT.gov ↗
What to watch
May 2027 (1)
Sacituzumab GovitecanPhase 1/2Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
Est. primary completion 2027-05 · NCT05101096 · CT.gov ↗
What to watch
June 2027 (2)
filgotinib · JyselecaPhase 3Polyarticular Course Juvenile Idiopathic Arthritis
Est. primary completion 2027-06 · NCT07554495 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3Triple Negative Breast Cancer
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch
August 2027 (2)
Est. primary completion 2027-08 · NCT07645287 · CT.gov ↗
What to watch
Lenacapavir (Sunlenca)Phase 2HIV-1 Infection
Est. primary completion 2027-08 · NCT07841990 · CT.gov ↗
What to watch
September 2027 (1)
Gamgertamig (CM336)Phase 3Multiple Myeloma (MM)
Est. primary completion 2027-09 · NCT07181239 · CT.gov ↗
What to watch
November 2027 (1)
Gamgertamig (CM336)Phase 1/2Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Est. primary completion 2027-11-18 · NCT07175493 · CT.gov ↗
What to watch
December 2027 (3)
TUB-040Phase 1/2Ovarian Cancer, Non-small Cell Lung Cancer
Est. primary completion 2027-12 · NCT06303505 · CT.gov ↗
What to watch
QuemliclustatPhase 2Advanced Non-Small Cell Lung Cancer
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
filgotinib · JyselecaPhase 3Juvenile Idiopathic Arthritis (JIA)
Est. primary completion 2027-12 · NCT07553182 · CT.gov ↗
What to watch
2028 (9)
March 2028 (1)
TUB-040Phase 1/2Ovarian Cancer
Est. primary completion 2028-03 · NCT07736937 · CT.gov ↗
What to watch
April 2028 (1)
Sacituzumab GovitecanPhase 3Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Est. primary completion 2028-04 · NCT05840211 · CT.gov ↗
What to watch
June 2028 (2)
Sacituzumab GovitecanPhase 1/2Triple Negative Breast Cancer
Est. primary completion 2028-06 · NCT06926920 · CT.gov ↗
What to watch
filgotinib · JyselecaPhase 3Ulcerative Colitis
Est. primary completion 2028-06 · NCT06865417 · CT.gov ↗
What to watch
July 2028 (2)
Sacituzumab GovitecanPhase 3Triple Negative Breast Cancer, PD-L1 Negative
Est. primary completion 2028-07 · NCT05382299 · CT.gov ↗
What to watch
Anitocabtagene autoleucelPhase 3Multiple Myeloma
Est. primary completion 2028-07 · NCT06413498 · CT.gov ↗
What to watch
September 2028 (1)
Lenacapavir (Yeztugo)Phase 3HIV Pre-exposure Prophylaxis
Est. primary completion 2028-09 · NCT07047716 · CT.gov ↗
What to watch
November 2028 (1)
Seladelpar · LivdelziPhase 3Primary Biliary Cirrhosis
Est. primary completion 2028-11 · NCT03301506 · CT.gov ↗
What to watch
December 2028 (1)
Seladelpar · LivdelziPhase 2Primary Biliary Cholangitis
Est. primary completion 2028-12 · NCT07841977 · CT.gov ↗
What to watch
2029 (7)
March 2029 (2)
Est. primary completion 2029-03 · NCT07682961 · CT.gov ↗
What to watch
Est. primary completion 2029-03 · NCT07683000 · CT.gov ↗
What to watch
May 2029 (1)
TUB-040Phase 2NSCLC, Non Small Cell Lung Cancer
Est. primary completion 2029-05 · NCT07806773 · CT.gov ↗
What to watch
June 2029 (1)
Sacituzumab GovitecanPhase 3Endometrial Cancer
Est. primary completion 2029-06 · NCT06486441 · CT.gov ↗
What to watch
September 2029 (2)
TUB-040Phase 1/2Uterine Endometrial Cancer
Est. primary completion 2029-09 · NCT07743541 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 2Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗
What to watch
October 2029 (1)
Sacituzumab GovitecanPhase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2029-10 · NCT06801834 · CT.gov ↗
What to watch
2030 (6)
April 2030 (1)
Sacituzumab GovitecanPhase 2Metastatic Urothelial Cancer
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
May 2030 (1)
Gamgertamig (CM336)Phase 3Multiple Myeloma (MM)
Est. primary completion 2030-05 · NCT07910903 · CT.gov ↗
What to watch
July 2030 (1)
Bictegravir/lenacapavir (Bixlenvo)Phase 2/3HIV-1-infection
Est. primary completion 2030-07 · NCT06532656 · CT.gov ↗
What to watch
August 2030 (1)
Seladelpar · LivdelziPhase 3Primary Biliary Cholangitis
Est. primary completion 2030-08 · NCT06051617 · CT.gov ↗
What to watch
October 2030 (1)
Est. primary completion 2030-10 · NCT07708727 · CT.gov ↗
What to watch
November 2030 (1)
QuemliclustatPhase 3Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2030-11-30 · NCT06608927 · CT.gov ↗
What to watch
2039 (1)
March 2039 (1)
Anitocabtagene autoleucelPhase 3Newly Diagnosed Multiple Myeloma
Est. primary completion 2039-03 · NCT07903506 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Anitocabtagene autoleucelPhase 3Newly Diagnosed Multiple Myeloma
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(11)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

23 December 2026FDA action dateAnitocabtagene autoleucelAnito-cel BLA PDUFA action date
US, FDA · Arcellx / Kite (Gilead) · Source ↗
2 February 2027FDA action dateLenacapavir (Yeztugo)PDUFA action date for once-weekly oral Yeztugo (lenacapavir) for HIV PrEP
US, FDA · Source ↗

Recent

27 August 2026ApprovalBictegravir/lenacapavir (Bixlenvo)FDA approves Bixlenvo for virologically suppressed adults with HIV
US, FDA · Source ↗
15 June 2026Filing acceptedLenacapavir (Yeztugo)FDA accepted Gilead's application for once-weekly oral Yeztugo (lenacapavir) for HIV PrEP
US, FDA · Source ↗
8 June 2026Topline resultSacituzumab GovitecanKEYNOTE-D46/EVOKE-03 (NCT05609968) Phase 3 discontinued: PFS primary endpoint not statistically significant
Merck and Gilead Sciences · Source ↗
8 June 2026Topline resultIslatravir/lenacapavirGilead and Merck: Phase 3 ISLEND-1 and ISLEND-2 of once-weekly oral islatravir/lenacapavir met their Week 48 primary endpoint
Gilead Sciences and Merck · Source ↗
2 June 2026Topline resultSeladelparIDEAL (NCT06060665) Phase 3 met its primary endpoint
Gilead Sciences, Inc. · Source ↗
23 February 2026Filing acceptedAnitocabtagene autoleucelFDA accepts anito-cel BLA for relapsed/refractory multiple myeloma
US, FDA · Arcellx / Kite (Gilead) · Source ↗
October 2024WithdrawalSacituzumab GovitecanGilead withdraws the US accelerated approval of Trodelvy in metastatic urothelial cancer
US, FDA · Gilead Sciences · Source ↗
12 September 2024Topline resultLenacapavir (Yeztugo)PURPOSE 2 topline: key endpoints met
Gilead Sciences · Source ↗
20 June 2024Topline resultLenacapavir (Yeztugo)PURPOSE 1 topline: key endpoints met
Gilead Sciences · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$8.3B$1.6B$6.4B+ $0 short-term inv.—$5.0B operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$7.8B$1.8B$3.2B+ $0 short-term inv.$10.5B$3.6B operating cash flowreport ↗
2026-Q1$7.0B$1.4B$7.6B+ $15M short-term inv.—$2.5B operating cash flowreport ↗
2025-Q3$7.8B$1.3B$7.3B+ $19M short-term inv.—$4.1B operating cash flowreport ↗
2025-Q2$7.1B$1.5B$5.1B+ $69M short-term inv.—$827M operating cash flowreport ↗
2025-Q1$6.7B$1.4B$7.9B—$1.8B operating cash flowreport ↗
2024-Q3$7.5B$1.4B$5.0B+ $0 short-term inv.—$4.3B operating cash flowreport ↗
2024-Q2$7.0B$1.4B$2.8B+ $0 short-term inv.—$1.3B operating cash flowreport ↗
2024-Q1$6.7B$1.5B$4.7B+ $0 short-term inv.$4.2B$2.2B operating cash flowreport ↗
2023-Q3$7.1B$1.5B$5.7B+ $1.2B short-term inv.—$1.8B operating cash flowreport ↗
2023-Q2$6.6B$1.4B$5.7B+ $963M short-term inv.—$2.3B operating cash flowreport ↗
2023-Q1$6.4B$1.4B$4.9B+ $936M short-term inv.—$1.7B operating cash flowreport ↗
2022-Q3$7.0B$1.1B$4.7B+ $961M short-term inv.—$2.9B operating cash flowreport ↗
2022-Q2$6.3B$1.1B$4.7B+ $924M short-term inv.—$1.8B operating cash flowreport ↗
2022-Q1$6.6B$1.2B$4.3B+ $1.0B short-term inv.—$1.8B operating cash flowreport ↗
2021-Q3$7.4B$1.1B$4.4B+ $1.4B short-term inv.—$3.3B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$29.4B$5.8B$7.6B+ $68M short-term inv.—$10.0B operating cash flowreport ↗

For full-year 2025, Gilead Sciences reported revenue of $29,443M, up 2.4% YoY, with R&D spend of $5,799M, down 1.8% YoY. The company ended the year with $7,564M in cash and equivalents, or $10,605M including marketable debt securities, and reported net income of $8,510M.

For 2026, Gilead guided to product sales of $29,600M–$30,000M, product sales excluding Veklury of $29,000M–$29,400M, Veklury of $600M, diluted EPS of $6.75–$7.15, and non-GAAP diluted EPS of $8.45–$8.85. Clinically, the company reported positive Phase 3 ARTISTRY-1 and ARTISTRY-2 results for its BIC/LEN HIV regimen, while Trodelvy’s ASCENT-07 study missed its primary endpoint and the Phase 3 STAR-221 study was discontinued. Other updates included a Yescarta label expansion, new data from the iMMagine-1, KITE-753/KITE-363, and ASSURE studies, the U.S. launch of Yeztugo, and a declared quarterly dividend of $0.82 per share.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$28.8B$5.9B$10.0B+ $0 short-term inv.—$10.8B operating cash flowreport ↗
2023-FY$27.1B$5.7B$6.1B+ $1.2B short-term inv.—$8.0B operating cash flowreport ↗
2022-FY$27.3B$5.0B$5.4B+ $973M short-term inv.—$9.1B operating cash flowreport ↗
2021-FY$27.3B$5.4B$5.3B+ $1.2B short-term inv.—$11.4B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 88 sales ($108.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Dickinson Andrew D · Chief Financial OfficerOpen-market sale3,000$171.47$514KForm 4
2026-11-16Mercier Johanna · Chief Comm & Corp Aff OfficerOption exercise25,000$72.34$1.8MForm 4
2026-11-16Mercier Johanna · Chief Comm & Corp Aff OfficerOpen-market sale13,922$169.97$2.4MForm 4
2026-11-16Mercier Johanna · Chief Comm & Corp Aff OfficerOpen-market sale13,178$171.09$2.3MForm 4
2026-11-16Mercier Johanna · Chief Comm & Corp Aff OfficerOpen-market sale900$171.69$155KForm 4
2026-11-16Mercier Johanna · Chief Comm & Corp Aff OfficerOption exercise (derivative)25,000——Form 4
2026-11-12Kramer Kelly A. · directorOption exercise10,376$66.92$694KForm 4
2026-11-12Kramer Kelly A. · directorOpen-market sale1,676$168.23$282KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,293 reporting institutions held 1058.3M shares ($140.2B, 85.3% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.119,010,973$16.6B
2VANGUARD CAPITAL MANAGEMENT LLC80,654,776$11.2B
3FMR LLC71,906,290$10.0B
4STATE STREET CORP59,858,585$8.3B
5Capital World Investors41,283,933$5.8B
6VANGUARD PORTFOLIO MANAGEMENT LLC35,129,465$4.9B
7JPMORGAN CHASE & CO33,992,410$4.6B
8GEODE CAPITAL MANAGEMENT, LLC29,726,052$4.1B
9Capital Research Global Investors27,127,533$3.8B
10Dodge & Cox24,250,826$3.4B
11MORGAN STANLEY23,299,295$3.2B
12BANK OF AMERICA CORP /DE/19,978,936$2.8B
13Invesco Ltd.15,526,336$2.2B
14Bank of New York Mellon Corp15,053,151$2.1B
15NORTHERN TRUST CORP13,820,379$1.9B